Cara Therapeutics Inc (CARA)
0.6843
-0.02
(-2.24%)
USD |
NASDAQ |
Apr 26, 16:00
0.6843
0.00 (0.00%)
After-Hours: 19:44
Cara Therapeutics Cash from Financing (TTM): 38.15M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 38.15M |
September 30, 2023 | 1.698M |
June 30, 2023 | 0.686M |
March 31, 2023 | 0.868M |
December 31, 2022 | 0.311M |
September 30, 2022 | 45.58M |
June 30, 2022 | 45.81M |
March 31, 2022 | 45.92M |
December 31, 2021 | 46.61M |
September 30, 2021 | 39.79M |
June 30, 2021 | 39.84M |
March 31, 2021 | 39.75M |
December 31, 2020 | 39.14M |
September 30, 2020 | 0.699M |
June 30, 2020 | 138.67M |
March 31, 2020 | 142.44M |
December 31, 2019 | 142.60M |
September 30, 2019 | 143.12M |
June 30, 2019 | 98.72M |
March 31, 2019 | 110.78M |
December 31, 2018 | 110.81M |
Date | Value |
---|---|
September 30, 2018 | 110.45M |
June 30, 2018 | 16.64M |
March 31, 2018 | 88.04M |
December 31, 2017 | 87.92M |
September 30, 2017 | 87.82M |
June 30, 2017 | 87.67M |
March 31, 2017 | 0.232M |
December 31, 2016 | 0.123M |
September 30, 2016 | -0.143M |
June 30, 2016 | 75.60M |
March 31, 2016 | 75.63M |
December 31, 2015 | 75.59M |
September 30, 2015 | 75.88M |
June 30, 2015 | 0.234M |
March 31, 2015 | 0.224M |
December 31, 2014 | 57.99M |
September 30, 2014 | 57.57M |
June 30, 2014 | 57.48M |
March 31, 2014 | 64.80M |
December 31, 2013 | 8.416M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.311M
Minimum
Dec 2022
143.12M
Maximum
Sep 2019
55.29M
Average
39.84M
Median
Jun 2021
Cash from Financing (TTM) Benchmarks
Nektar Therapeutics | 0.03M |
Stereotaxis Inc | 0.081M |
Cerus Corp | 10.67M |
Avid Bioservices Inc | 8.937M |
Rigel Pharmaceuticals Inc | 18.37M |